Search

Your search keyword '"Anne Bourrier"' showing total 89 results

Search Constraints

Start Over You searched for: Author "Anne Bourrier" Remove constraint Author: "Anne Bourrier"
89 results on '"Anne Bourrier"'

Search Results

1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

2. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trialsResearch in context

3. Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study

4. Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

5. Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease.

6. Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study

7. Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID

8. Multidisciplinary support for ethics deliberations during the first COVID wave

9. IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-α blockers

10. Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases

11. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study

12. Prevalence of anti-TNF contraindications in Crohn’s disease: A cross-sectional survey from the GETAID

13. Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID

14. Intraoperative random biopsies of strictureplasty sites can detect early small-bowel adenocarcinoma in patients with Crohn's disease

15. Comparative Real-World Effectiveness of Vedolizumab and Ustekinumab for Patients with Ulcerative Colitis: A GETAID Multicentre Cohort Study

16. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

17. Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group

18. Impact of Aphthous Colitis at Diagnosis on Crohn’s Disease Outcomes

19. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study

20. Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

21. P504 Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

22. Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study

23. Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study

24. Corrigendum to: Diagnostic Yield of Next-Generation Sequencing in Very Early-Onset Inflammatory Bowel Diseases: A Multicenter Study

25. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients

26. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

27. Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection

28. A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis

29. Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn’s Disease

30. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study

31. P248 Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease

32. P719 Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study

33. Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia

34. Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)

35. P711 The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study

36. Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective study

37. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study

38. Mo1800 – A Simple Scoring Tool Predicts Exposure-Response Relationship, Onset of Action, Response to Interval Shortening, and Surgical Risk with Vedolizumab Therapy for Crohn’s Disease

39. P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease

40. Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?

41. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands

42. Fungal microbiota dysbiosis in IBD

43. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti-Tumor Necrosis Factor Agents

44. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease

45. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort

46. Factors affecting outcomes in Crohn's disease over 15 years

47. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

48. DOP011 Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAID

49. P199 Hidradenitis suppurativa associated with Crohn’s disease: An increased risk of permanent stoma

50. Changes in the Lemann Index values during the First Years of Crohn's Disease

Catalog

Books, media, physical & digital resources